Terms: = Bone cancer AND XPC, XP3, 7508, ENSG00000154767, XPCC AND Treatment
3 results:
1. A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation.
Heimann SM; Vehreschild MJ; Cornely OA; Franke B; von Bergwelt-Baildon M; Wisplinghoff H; Kron F; Scheid C; Vehreschild JJ
Eur J Haematol; 2015 Jun; 94(6):526-31. PubMed ID: 25310918
[TBL] [Abstract] [Full Text] [Related]
2. Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors.
Sun XH; Hou WG; Zhao HX; Zhao YL; Ma C; Liu Y
Asian Pac J Cancer Prev; 2013; 14(3):2049-52. PubMed ID: 23679317
[TBL] [Abstract] [Full Text] [Related]
3. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract] [Full Text] [Related]
